Criteo S.A.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Wells Fargo cut Criteo's (CRTO) price target to $15 from $16, citing FX headwinds, while maintaining an Equal Weight rating. The stock trades near its 52-week low. Despite Q2 2026 earnings beating estimates, Criteo reduced its future outlook, causing investor concern. Analysts have mixed views, with Bernstein downgrading and StoneX maintaining a Buy rating.
StoneX maintained a Buy rating and $21.00 price target for Criteo (CRTO) after a meeting with the company, citing AI progress and undervaluation. CRTO trades at $16.50, with 27% upside potential. Revenue declined 4.2% over the last year, but earnings beat estimates in Q2 2026. Bernstein SocGen downgraded CRTO to Market Perform, citing profit warning concerns.
CVS Health and Criteo agreed to a $20.5M settlement for alleged data privacy violations. The lawsuit claimed CVS shared patient health data with Criteo via web trackers without consent. The settlement covers U.S. users of CVS digital properties before July 27, 2026, with potential payouts of $5-$10 per class member. CVS and Criteo deny wrongdoing. A final approval hearing is set for Dec. 1.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CRTO (Criteo S.A.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent CRTO coverage spans insider activity, financial news and regulation.
In the last 30 days, CRTO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($2K). The most active reporter was McGogney Connor, Chief Financial Officer, with 1 filing.
Analyst downgrades and lower price targets suggest near‑term downside pressure.
Analyst upgrade may support upside to current price.
Criteo faces similar reputational risk and may see a slight share dip.
Criteo faces similar risk reduction from settlement approval.
Minor dilution from insider share sale; limited price impact.
AlphAI scores every news story that mentions CRTO with an AI model for sentiment and relevance, and aggregates insider trades from Criteo S.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo cut Criteo's (CRTO) price target to $15 from $16, citing FX headwinds, while maintaining an Equal Weight rating. The stock trades near its 52-week low. Despite Q2 2026 earnings beating estimates, Criteo reduced its future outlook, causing investor concern. Analysts have mixed views, with Bernstein downgrading and StoneX maintaining a Buy rating.
2 min readStoneX maintained a Buy rating and $21.00 price target for Criteo (CRTO) after a meeting with the company, citing AI progress and undervaluation. CRTO trades at $16.50, with 27% upside potential. Revenue declined 4.2% over the last year, but earnings beat estimates in Q2 2026. Bernstein SocGen downgraded CRTO to Market Perform, citing profit warning concerns.
2 min readCVS Health and Criteo agreed to a $20.5M settlement for alleged data privacy violations. The lawsuit claimed CVS shared patient health data with Criteo via web trackers without consent. The settlement covers U.S. users of CVS digital properties before July 27, 2026, with potential payouts of $5-$10 per class member. CVS and Criteo deny wrongdoing. A final approval hearing is set for Dec. 1.
2 min readA US judge is set to approve a $32 million settlement for GoodRx and Criteo, resolving privacy allegations. This is the third iteration of the settlement. Both companies are involved in the case.
1 min readCriteo CFO Connor McGogney filed a Rule 144 notice for a 758-share sale to cover tax withholding from restricted stock unit vesting on March 1, 2024, at an indicative price of $17.5004 per share. The filing also lists prior share sales by McGogney over the past three months.
1 min readCriteo (CRTO) shares rose 21% after receiving a takeover offer from Vista Equity Partners and Quinti Capital, valuing the company at over a 50% premium. The bid is non-public, and details are undisclosed. Criteo's board will review the proposal. Rival Trade Desk (TTD) shares also gained 1%.
2 min readGlickman Sarah JS (Chief Financial Officer) sold 6,285 shares of Criteo S.A. (CRTO) at $17.23 ($0.11M total) on 2026-08-06.
2 min readDamon Ryan (Chief Legal Officer) sold 6,178 shares of Criteo S.A. (CRTO) at $17.23 ($0.11M total) on 2026-08-06.
1 min readKomasinski Michael (CEO) sold 15,559 shares of Criteo S.A. (CRTO) at $17.23 ($0.27M total) on 2026-08-06.
2 min readMorgan Stanley lowered its price target on Criteo S.A. to $25 from $29 while keeping an Equalweight rating, according to the note cited in the article. The update was published Aug. 6, 2026. The change may affect investor expectations for the stock’s valuation.
1 min read